ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP). ImprimisRx currently provides a limited number of ophthalmic formulations to practices within the ESP group, but this agreement will expand the number of formulations available to new and existing ESP facilities and allow for additional formulations to be added as the ImprimisRx/ESP relationship continues to expand. ESP is a partnership of 30+ ophthalmologic, optometric brands, and ambulatory surgery centers (ASCs) across multiple states, with 90 locations, 12 ASCs, and 200 providers, representing approximately 100,000 ophthalmic procedures in the U.S. annually.

Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Harrow Health, Inc. (HROW) today announced that after the close of trading on Monday, May 11, 2020, it will release first quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time to discuss the financial results and recent business developments. After the close of the market on May 11, 2020, Harrow will issue a press release containing a link to its first quarter 2020 Letter to Stockholders. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction, an overview of the quarter, and outlook for the business.

Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

While it is difficult to predict what the rest of 2020 will look like, we are starting to see orders come in as our customers re-open and we continue to be excited about Harrow’s upcoming events, catalysts, and developments in the near and long-term. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, Mayfield and Radley.

Novel Drug Solutions, LLC and Eye Care Northwest, PA, announce the return of their unrestricted patent rights to several awarded and pending USA and international patents previously controlled by Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt® and various injectable and topical products.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Harrow Health, Inc. (HROW) today announced the appointment of Teresa Sparks to its Board of Directors. As Harrow continues to drive shareholder value by founding, developing, and deconsolidating companies like Eton, Surface, and Melt, I anticipate Teresa’s impressive experience as a healthcare leader of both private and publicly traded companies will be an invaluable asset.

Is Harrow Health, Inc. (NASDAQ:HROW) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest analyst coverage could presage a bad day for Harrow Health, Inc. (NASDAQ:HROW), with the analysts making...

Harrow Health, Inc. (HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time to discuss the financial results and recent business developments. Prior to the open of the market on March 13, 2020, at approximately 8:00 a.m. Eastern Daylight Time / 5:00 a.m. Pacific Daylight Time, Harrow will issue a press release containing a link to its fourth quarter 2019 Letter to Stockholders. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction and overview of the quarter and outlook for the business.

Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with Vision Center Network of America, LLC (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products.

Harrow Health, Inc. (HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow, announced that they have entered into an exclusive agreement with Doxy.me, a full-service telemedicine solution. Doxy.me is one of the largest, yet simplest, telemedicine software solutions in the world, providing video, audio and text through which patients and healthcare providers can seamlessly communicate remotely.

Mark Baum has been the CEO of Harrow Health, Inc. (NASDAQ:HROW) since 2012. This report will, first, examine the CEO...

The company is not expecting disruptions in its business or supply chain as a result of the recent COVID-19 virus concerns in the US and around the world. The company has double checked inventories and its sources of key active pharmaceutical ingredients and other materials. In addition, the company has been in contact with its insurance provider and believes it has adequate coverage through its various risk management policies that could help supplement any losses in the unlikely event a potentially recoverable claim was to occur.